Probi Signs Distribution Deal for Greece, Cyprus
Alapis Group is based in Athens, Greece with a turnover of €1,232.5 million in 2009 and more than 1,700 employees. The Group has had a proactive growth and acquisition strategy which has resulted in a strong presence in Southeast Europe.
8 Dec 2010 --- Probi has signed a distribution agreement giving Alapis Group the right to sell Probi’s dietary supplement for immune health in Greece and Cyprus. Alapis Group, based in Greece, is set to be one of the leading pharmaceutical companies in Southeast Europe. The product will be launched under Alapis international probiotic brand, which currently carries two products. Probi will start shipments in the second quarter of 2011 and the product will be launched into Greek pharmacies in the third quarter.
“Alapis Group is a perfect partner for Probi in Greece, with a strong presence and track record in Southeast Europe. The launch in Greece is another important milestone for this new product and it is the sixth market where Probi enters into a distribution agreement for the immune tablet,” says Michael Oredsson, CEO of Probi.
Alapis Group is based in Athens, Greece with a turnover of €1,232.5 million in 2009 and more than 1,700 employees. The Group has had a proactive growth and acquisition strategy which has resulted in a strong presence in Southeast Europe. The Group operates in Turkey, Bulgaria, Romania, Cyprus, Serbia, Croatia, as well as UK.
“There is an increasing demand for probiotics in Greece. Probi’s immune product is clinically documented in immune health and common colds and will be sold as a chewable tablet in pharmacies. We are convinced that a successful launch will grow the product category and open for more synergies and new geographies,” says Mr. Stylianos Kibaridis, CEO of Alapis S.A. in Greece.
Dietary supplements based on Probi’s immune probiotics are now sold or are in the process of being launched in some six countries worldwide.
